The Chozn platform enables faster, simpler selection and scale-up of high-producing clones for the production of recombinant protein drugs.
The new platform consists of the cGMP-produced and tested Chozn ZFN Modified GS-/- CHO cell line, the commercially available glutamine synthetase (GS) knockout CHO line proven to shorten bioproduction times.
SAFC Cell Sciences and Development director Bruce Lehr said the Chozn platform provides a solid foundation for the company’s continued cell and media development program.
"It has been proven to show a reduction in product development timelines, enabling customers to get their molecules into the clinic faster," Lehr added.
"Furthermore, it sets the stage for future cell line enhancements to affect characteristics like protein quality, molecule safety and efficacy, as well as improvements to upstream or downstream biopharmaceutical process development."